Skip to main content
. Author manuscript; available in PMC: 2016 Feb 8.
Published in final edited form as: J Bone Miner Res. 2013 Jan;28(1):92–107. doi: 10.1002/jbmr.1732

Fig. 5.

Fig. 5

CB2 agonist decreases 66.1 breast cancer proliferation in vitro and in vivo. (A, C) SRB assay indicates breast cancer cells (66.1) treated with JWH015 or AM1241 demonstrate a concentration-related decrease in their viability over a 48-hour period in a six-well plate compared to vehicle-treated cells (p ≤ 0.001; n = 18 per group). (B) Tumor burden using H&E staining of a femoris from intrafemoral cancer animals administered either vehicle or JWH015. JWH015 reduces the number of 66.1 cells within the intramedullary space compared to vehicle-treated animals (p = 0.01; n = 4 per group). (D) BrDU assay demonstrates breast cancer cells (66.1) treated with JWH015 decrease their ability to proliferate in a 96-well plate compared to vehicle treated cells; this effect can be reversed by the CB2 antagonist/inverse agonist SR144528 but not CB1 antagonist/inverse agonist SR141716 (p = 0.0001; n = 6 per group).